
veeva system inc vertic cloud softwar
commerci cloud busi veeva help
veeva vault busi compani
provid content manag data tool life
scienc develop commerci organ
assur compliant medic commun
reason report
initi coverag
first veeva except busi uniqu combin
compani deliv remark result last seven year
second like life scienc end market growth
share get compani ambit outsid life scienc
nice fourth forecast continu strong consensu revenu
posit dynam think multipl bit stretch
histori veeva start launch sale
autom tool pharmaceut sale rep built top
develop side life scienc veeva
launch veeva vault suit applic first center
submiss qualiti document see success
commerci cloud stat mil expect revenu
total subscript revenu growth
bil bil depend calcul
across develop commerci organ unlik
import disclosur analyst certif page report access current disclosur
stephen inc cover compani client may refer
-- -- -- -- -- -- page intent left blank -- -- -- -- -- --
initi coverag
geograph segment split
drive stock
vital gener strong ls industri
suit growth ok year
vault growth engin
vault outsid life scienc call option
margin pois out-performance
risk invest thesi
busi snapshot product deep dive
manag board
pharmaceut biotech compani commerci
veeva vault busi compani provid content
manag data tool life scienc develop
assur compliant medic commun
mil revenu grow
adj ebit margin
short interest float
mil vote power
includ factset consensu
estim mil except epsstephen inc estimateconsensu estimateguidancetot estim mil except epsstephen inc estimateconsensu estimateearli outlooktot bil adj busi segment snapshot
total
revenu market size
total
revenu market size
mix cross sell
relat tool help pharma biopharma sale
content manag data applic address core
rep sell better ensur complianc
need life scienc busi across develop
built salesforc com platform
built proprietari veeva platform host aw
commerci cloud custom tend larg pharma biotech
vault product address compani commerci
compani big commerci product
develop phase longer tail term custom
market larg pharma/biotech approv product
market pharma/biotech med devic
seven year veeva grown revenu
mil mil org growth compound-annual-growth-rate
mil
veeva expand adj ebit margin
exceed wacc fiscal year
sinc veeva came public year
best yet
mil
wacc
veeva fundament growth margin expans return profil point solid busi model
note wacc use bloomberg data use nopat model calcul invest capit
waccveev geograph segment split
mil
mil
 servicesprofession servic americaeurop otherasia pacif stock chart
scotu rule
state collect sale
tax purchas
total return stock
outperform
softwar market three year
perform roughli in-lin market
last year
revenue outlook touch light
consensu like conserv
biggest day
biggest day
nice last twelv month driven four strong quarter
total return div servic ipo setup
last year trade
ev/ntm rev current sit
last year trade
ev/ntm rev averag
last year averag
trade ev/rev multipl
saa peer share current trade
premium
trough
ev/ntm rev current trade peer vs averag premium
peer group saa comp group page
framework isol factor believ greatest potenti impact stock price next twelv
month break apart driver specif alpha-sid driver vs broader market driver beta-sid driver
small driver ntm
driver stock perform ntm revenu bill adj ebit
chang sentiment
biggest contribut factor revenu bill margin ntm
core vault product core add-on infrastructur
leverag new vault vault ol small impact
financi perform ntm key ntm sentiment
moder lever market
beta
infinit number potenti contribut factor
market correct variou econom trend
chang consum credit trend trade war turn
focu research contribut factor revenu bill profit sentiment keep eye macro
call first veeva except busi sell mission-crit saa applic life scienc industri
primarili pharma biotech contract research organ veeva uniqu combin technolog excel
industri expertis enabl compani deliv remark result seven-year organ revenu compound-annual-growth-rate
adj ebit margin expans second like life scienc end market growth lack
cyclic third like call option owner share get compani seek expand presenc outsid
life scienc opportun character larg earli progress nice fourth forecast continu strong
consensu revenu growth strong above-consensu profit growth despit posit dynam think
valuat twelv month price target base ev/ntm multipl one year today page
multipl bit stretch wait better entri point
full valuat justif
vital gener strong life scienc industri
suit growth ok year
driver growth
vault growth engin
next leg growth cdm safeti
vault outsid life scienc call option
bil
promis opportun earli success
margin pois out-performance
conserv margin model put us rang
vital gener strong life scienc industri pharma revenu
matter
mil
geograph split drug revenu
worth
worth
worth
forecast compound-annual-growth-rate
risk patent cliff includ humira global drug revlim
fuel person treatment
fuel growth emerg market
unclear quickli biosimilar take share due modest
discount innov lower substitut pharmaci
pharma revenu growth expect matter veeva live downstream revenu
evalu pharma fiercepharma european feder pharmaceut industri associ stephen inc
vital gener strong life scienc industri clinic trial
matter
regist trial
studi
observ
 conduct
goal
non-
drug
biolog devic
phase
phase
look data get direct feel trend clinic trail
believ recent long-term trial growth healthi
saw y/i growth number regist clinic trial oct look like full year doubl digit
number clinic trial grow low teen percentag matter trial drive veeva vault develop cloud
oct
vital gener strong life scienc industri sale rep
matter
rough global split
 sale rep headcount declin number
blockbust drug came patent includ lipitor
 rep count rel stabl sinc
 small portion
think europ trend similar
 emerg market grow
reason believ rep count data entir accur
think use direct driver
best estim global rep count
 europ rep growth lacklust emerg mkt better matter fuel spend add-on product
suit growth ok year
product includ core add-on approv email medcomm align event network opendata
engag product sold pharmaceut compani commerci asset
pretti high penetr bottom
veeva broad
look servic
spend pharma
mil app
global sale rep
app
mil data network
mil nitro
flat/declin pharma rep europ
pharma rep visit often report redund
flat/declin doctor access
shift focu big indic drug like statin
person medicin chang rep doctor
rise ai help engag doc better
continu adopt modern engag
offset growth emerg market
dynam increas penetr little/no growth eventu limit suit growth
suit growth ok year driver growth
veeva growth reli mostli share take core add-on product give exampl growth
growth new seat
growth add-on
driver commerci cloud growth
exampl seat-add deal
exampl add-on deal
top pharma expand rep
top pharma expand rep
top pharma expand
emerg market latam apac
see win align event
sign three top pharma event
top pharma bought event
sign top pharma hq japan
sign three top pharma clm
sign two top pharma
one top pharma japan
sign two biotech launch
approv email along also expand
opendata deal top china pharma
top pharma bought align opendata
network anoth top pharma
custom expand network opendata
commerci cloud growth split new seat add add-on sale
suit growth ok year growth model
growth discuss boil price quantiti observ histor quantiti trend measur number
instal commerci product approv email medcomm align event network opendata engag nitro
number commerci instal
veeva grow custom count product instal count product per custom
product instal count grow nearli fast custom count grow indic veeva
gain wallet share within base
veeva grow number commerci custom number product sell custom
 commerci installationsnumb commerci customersavg commerci product per commerci custom
suit growth ok year growth model
growth discuss boil price quantiti observ histor price trend measur number
instal commerci product approv email medcomm align event network opendata engag nitro
mil
estim averag price declin compound-annual-growth-rate last year
declin average price larger share increment sale lower price add-on sold
veeva sell commerci base experienc averag price compress driven think mix shift
suit growth ok year growth model
mil
revenu growth
growth
forecast veeva
nearli third
could caus veeva
beat estim
mil
veeva earli
forecast commerci cloud sub growth
vault growth engin
summari near- long-term growth compon
mil
launch custom cross sell
cdm launch edc rebrand cdm
biggest vault opportun still young today
qualitydoc qm execut drive adopt growth
submiss registr archiv launch submiss
other continu march toward adopt
benefit cloud pharma buy
usual roll global gate growth driver today
publish earli adopt phase smaller piec regulatori
safeti roll earli spend year
promomat launch upsel zinc custom higher-
medcomm launch smaller product cross sell base
bil vault tam life scienc give room mani year growth
vault growth engin high level valu prop
vault softwar fit drug develop process
safeti
veeva product help life scienc compani walk molecul clinic trial regulatori submiss approv
commerci ensur patient safeti product qualiti govern complianc
mostli premis
flexibl
integr
integr app connect ecosystem
result faster better develop
veeva vault product address entir develop process offer strong valu proposit vs legaci technolog
vault growth engin current growth driver
etmf electron master file mil market veeva
gain leadership posit boast custom
custom year ago even strong
adopt still plenti room grow new
exist custom veeva refer sell mode
two quarter ago veeva best etmf quarter
term sign new busi
critic mass sponsor realli acceler
top cro standard etmf
best quarter new busi sign
qualiti suit consist qualitydoc content
manag qm qualiti manag system data
app monitor manag manufactur qualiti veeva
lot room go mil market
custom yoy expect qualiti one veeva
main vault revenu driver next three year
product proven posit acceler growth
ad train complet suit
first top europ win alreadi top
regulatori suit consist submiss registr
submiss archiv publish mil market
custom yoy rim sit touch qualiti
term adopt veeva built product recent
ad publish complet suit focu
deepen product featur function
rim purchas often roll global
gate
top pharma bought rim global
oper top
largest rim go-liv date top pharma
believ etmf qualiti rim vault revenue drive vault growth next sever year
vault growth engin growth
clinic trial manag system data applic
launch mil complex
product sit center clinic trial plan
execut sign first earli adopt year ago sign
first top pharma last quarter sold
etmf custom would expect faster adopt
vs veeva experienc etmf last year
custom sign live
custom sign nearli etmf cross
cdm clinic data manag system veeva biggest
opportun product around bil cdm
core databas data trial record veeva
earli adopt locked/clos first two
trial veeva see good earli progress compar
week almost real-tim data extract lower complex
success close complet first two trial oct
see prior trial user sign trial
close first two studi custom sign
trial
first top pharma win phase trial
safeti applic life scienc compani system patient advers event record analyz
mil market veeva start enter like cdm think safeti provid leg vault growth stori
year product slate launch earli pharma need safeti system expens clunki system
especi burdensom smaller pharma biotech
veeva cut teeth smb market start work product enter refer sell mode year
cdm safeti repres bil veeva start address believ next leg growth
vault growth engin growth model
mil
subscript growth
think veeva could beat
estim given larg
opportun
headcount growth ad
sale engin
model assum
grow per year
view
veeva ad
headcount least quickli
forecast veeva maintain mid/high vault subscript revenu growth think conserv
sub dollar growth growth
vault outsid life scienc call option
vault outsid life scienc ol appli core vault applic compani regul manufactur
environ includ compani cpg space cosmet certain industri applic chemic
dream dream
veeva reput life scienc give
veeva expect mil ol rev
credibl industri
like life scienc lot legaci tech
industri
veeva balanc sheet potenti make
acquisit would give domain expertis
initi market presenc
veeva ol field sale dozen
much inbound interest yet reput yet
view ol call option nice opportun think meaning revenu sever year
margin pois out-performance
last three year veeva expand adj ebit margin per
conserv model virtual zero margin expans
even modest estim put adj ebit margin rang
veeva provid octob investor day translat expect margin out-performance
conserv margin model put veeva adj ebit margin rang
risk invest thesi
drug price legisl extent drug legisl
execut action lower drug price would like drive price
pressur product may also dampen
invest new develop project thu affect growth
veeva vault busi
iqvia anti-competit behavior lawsuit last
year iqvia made difficult/imposs custom
put iqvia data veeva network mdm app continu
today veeva su iqvia practic iqvia also
su veeva claim gain unauthor access
iqvia data trade secret matter go trial late
believ issu dampen growth veeva
data network busi
competit host competitor legaci
modern commerci side
develop side veeva built busi take share
player risk competitor
increas product invest make difficult
veeva compet
regul pharma sale regul pass
market limit activ pharma rep may
caus pharma compani cut
pressur growth veeva commerci
pharma consolid mani non-issu
case larg merger one pharma compani consolid
other system could posit neg
veeva depend veeva system part surviv
plan combin compani decid trim sale rep
headcount realiz cost synergi
custom concentr veeva top custom account
total compani revenu think top three
around total revenu
salesforc relationship veeva built sale autom
tool salesforc platform pay salesforc fee
platform agreement goe sep risk
salesforc cancel contract point begin
compet veeva open door isv see
unlik given veeva pay fee salesforc amount
around annual commerci subscript revenu
vault outsid life scienc unproven veeva act
ambit outsid life scienc launch
qualityon unproven opportun today immateri
revenu believ portion posit sentiment
ride opportun
data breach softwar disrupt alway risk saa
busi risk heighten given sensit
data veeva control patient data trial data drug product
data etc believ veeva industry-lead secur
infrastructur help mitig risk much
possibl unawar data breach regard veeva
past
econom downturn life scienc rel recession-
resist industri less worri macro
veeva softwar compani still
potenti slow tech invest veeva growth
current premium peer
vs average premium
assum peer hold
current mult
revers come yr
mil ex ep
model veeva put
mid/high vault revenu
growth coupl
conserv
come year expect
growth ntm estim
peer includ equal-weight index saa comp group see page
peer trade averag ev/ntm rev
twelv month price target base trade ev/ntm revenu multipl one year today
believ share deserv premium peer compani strong expect growth
uncommonli high margin cash flow custom base gener recession-resist real shot
own life scienc vertic market transit saa
peer trade ev/rev price target base appli ev/rev multipl ntm rev one year today
million except per share data price float dollar volume adob inc on-demand softwar softwar hold inc class desk inc class softwar group system inc class inc class compani document stephen inc note bold estim stephen inc estim other factset consensu ev/rev nm price-to-earnings nm ev/ebitda nm changeadj ep p/erevenu ev/rev valuat discount gut check termin valu method
acknowledg output dcf swing meaning base assumpt use use dcf answer
question assum long-term growth profit discount rate etc order justifi price target
termin valu dcf produc price target assum termin multipl
inc discount valuat termin multipl method dollar million except per share data project best approxim calendar year termin enu ev termin ev year adj ev year increment ebitda net adj market less tax share depreci per share less capit less chang net work unlev free unlev ev year jame rutherford analyst compani document stephen inc best approxim calendar year-end exmpl best approxim fy end jan year valuetot valu valuat discount gut check perpetu growth method
acknowledg output dcf swing meaning base assumpt use use dcf answer
question assum long-term growth profit discount rate etc order justifi price target
multi-stag termin growth dcf produc price target assum termin growth rate start yr
inc discount valuat multi-stag termin growth method dollar million except per share data project best approxim calendar year year growth rate year year year adj ebitda depreci year perpetu growth discount termin less tax depreci less capit ev year less chang net work ev year unlev free ev year unlev less net market share ev year per share jame rutherford analyst compani document stephen inc best approxim calendar year-end exmpl best approxim fy end jan year year valuetermin valu base perpetu growth in-depth report
total
revenu market size
total
revenu market size
mix cross sell
relat tool help pharma biopharma sale
content manag data applic address core
rep sell better ensur complianc
need life scienc busi across develop
built salesforc com platform
built proprietari veeva platform host aw
commerci cloud custom tend larg pharma biotech
vault product address compani commerci
compani big commerci product
develop phase longer tail term custom
market larg pharma/biotech approv product
market pharma/biotech med devic
veeva product drug life-cycle
safeti
integr etmf driver
trial execut
on-tim budget
trial plan
etmf custom
stay
manag system
clinic trial repositori
essenti document
trial requir regul
brochur scientif info
drug sign trial protocol
info paper given trial
system better visibl
studi start-up help
site trial first top
pharma earli adopt small
market add-on sale
siteexchang way pass
document pharma
compani cro trial site
secur without email
complet lock first
success build success
store trial
data workbench code
health data paper
enter edc faster
result fewer error
control health issu
pop
veeva product drug life-cycle cont
safeti
size client total rim
mil total rim
get
product approv
plan author
submiss doc regul
doc integr
qualitydoc qualiti
use submiss write
submiss document
size client total rim
mil total rim
give visibl
pharma employe
registr statu across
product geographi
info veeva cloud
right document
exampl pharma employe
 receiv request see
approv letter drug xyz
japan hop cloud
find need email
pharma went live
rim
pharma went live
rim
launch late
store submiss secur
format submiss
requir inform
exact correct format
regul someth
client request
veeva product drug life-cycle cont
safeti
size launch earli
safeti depart life
complianc ensur safeti
size top use
store
relat manufactur
safe secur place
control document
store contract
manufactur access
upload batch report
sponsor review integr
rim qualiti doc
includ submiss
trend unif qualiti
management system cloud
use monitor control
qualiti product
specif track deviat
sop audit look
equip failur look
qm specif sop dig
whether product
implement capa action issu
wont happen
trend unif qualiti
management system cloud
adopt
current hard
know train
lot manual
manufactur
employe train
regulatori
trend type
train alreadi
requir veeva
custom bring
offer in-hous
cross-sel exist
veeva product drug life-cycle cont
safeti
high attach rate
growth quit strong driven zinc
convers ad smaller custom
make sure promot
tv radio print etc accur
specif help ls compani manag
end-to-end process creation review
distribut tv radio on-line ad
ad agenc make new ad
send medic legal regulatori
review final approv
handl within promomat platform
trend migrat last zinc custom
growth larg busi
accur compliant
medic commun healthcar
profession patient
specif streamlin way creat
approv deliv singl sourc
medic content verbal written
commun public
exampl pharma co write side effect
new drug push thru channel go
print channel also use
servic depart answer incom
question risk
veeva product drug life-cycle cont
safeti
mil clm
enabl
pharma sale rep sell
optim interact built
review past purchas
go meet rep
medic materi
fingertip sale pitch
trend recent major
upgrad sunris ui
size attach rate
mil clm
put digit
market content sale
rep fingertip mobil
exampl rep walk
physician offic show data
new drug pull
custom buy clm
time
size attach rate
mil clm
enabl rep
email physician
align tool optim sale
specif thing rep
tool sale rep
say physician highli
control dont make
drug person physician
email next day follow
trend grow usag
affili veeva keep
oncolog link market intel
leader oncolog
network cleans
custom product data
veeva product drug life-cycle cont
safeti
 maintain
 alway date
size sign first hand earli
product earli adopt input
mil address ls
compani commerci
launch ga late
data warehous
combin data mani sourc
data parti data etc make
use bi ai
wareh sync
promomat custom activ data
product info
warehous foundat big data
analysi ai improv sale
 rebuild warehous
financi term disclos
foundat opendata product
lead global provid
opinion leader kol data
servic life scienc market
essenti data help
target engag plan
import doctor order
merg veeva data offer
commerci cloud
announc close
found base uk
mil run rate rev time
deal modestli accret
adj ep synergi
zinc map product
competitor promomat
ls custom time
solut releas serv
zinc ahead custom
busi veeva
time deal
tap lead veeva commerci
convert zinc ahead custom
veeva platform time
continu use zinc
map offer support
least
veeva made acquisit one zinc market share play qforma build data product
amcstephen inc estimateconsensu estimatepre-quart guidanceactualtot tax amcstephen inc estimateconsensu estimatepre-quart guidancenew guidancetot amcstephen inc estimateconsensu estimatepre-quart guidancenew guidancetot mil except per share data otherwis amcstephen inc estimateconsensu estimatepre-quart guidanceactualtot tax amcstephen inc estimateconsensu estimatepre-quart guidancenew guidancetot amcstephen inc estimateconsensu estimatepre-quart guidancenew guidancetot mil except per share data otherwis amcstephen inc estimateconsensu estimatepre-quart guidanceactualtot tax amcstephen inc estimateconsensu estimatepre-quart guidancenew guidancetot amcstephen inc estimateconsensu estimatepre-quart guidancenew guidancetot sub yoyvault sub yoyadj mil except per share data otherwis amcstephen inc estimateconsensu estimatepre-quart guidanceactualtot tax amcstephen inc estimateconsensu estimatepre-quart guidancenew guidancetot earli amctabl inc estimateconsensu estimatepre-quart outlookearli outlooktot least sub -- -vault sub -- -adj share -- -adj mil except per share data otherwis note corpor histori
found peter gassner
matt wallach
launch
launch europ
jim cabral join new cfo
commit becom multi-product compani
launch ipad
launch japan
nitsa zuppa join chief market offic
alan mateo join evp global sale
acquir zinc ahead mil
acquir qforma mil
launch engag meet webinar
henri levi join chief strategi offic
commit becom multi-industri compani
launch new sunris ui
earli career staff
develop vice-president
gm peoplesoft
svp technolog salesforc
integr
platform
serv board zoom
help build veeva year
experi variou role
previous gm pharma
biotech divis siebel system
establish co
market leader pharma
join veeva key
ipo
previous cfo/coo walsh
founder agist
vice-president financ peoplesoft
serv board apttu
join veeva
also presid industri
md lead
global life scienc
role accentur
join veeva
previous evp field op
role medidata solut
gvp product
line sale peoplesoft
join veeva
expertis market
respons brand
enabl product market
previous exec director
first group
variou leadership role siebel
veeva manag team deep experi technolog life scienc
board director
veteran tech ventur capitalist earli investor veeva
founder gener partner emerg capit
emerg histori success invest includ veeva notabl
mil invest salesforc
prior emerg mr ritter co-found softwar servic marc
benioff ceo salesforc softwar servic becam foundat
salesforc platform
previou page bio
veteran ls industri
held varieti senior execut
role affymetrix human genom
scienc career
board arqul selectra
previous
variou role includ bea
system bell
lab mr carg began career
also serv board
year md
co-head tech bank
particip mani notabl tech ipo
sinc oper financi
board
briefli interim ceo
ultracel corp fuel cell compani also
cfo svp variou role
peoplesoft seven year
also director
oper partner highlin therapeut
biotech incub presid ceo
lyceria biotech focus autoimmun
previous svp sanofi chief strategi
offic teva variou senior role tpg
pharmaceut new ventur
veeva board deep experi technolog oper life scienc technolog invest
ownership
vote power
ownership
vote power
transfer ownership
 share result
share convert
inc incom statement dollar million except per share data fyefyefyefyefyefyefor three month end fyefor three month end fyefor three month profession servic total profession servic total oper gross other- total oper oper expens earn incom provis incom oper net less one-tim items- net adj basic share dilut share adj effect tax rate subscript servic servic revenu revenu organ constant net gross gross gross total gross margin expans contract bpsadj ebit ebit margin expans contract bpsincrement adj ebit ebitda ebitda margin expans contract bpsincrement adj ebitda net reconcili net stock-bas amort purchas intangibles- less capit intern use amort intern use other- less tax impact add-backs- adj net oper gross stock-bas amort purchas intangibles- amort internal-us software- other- adj gross oper stock-bas amort purchas intangibles- less capit intern use amort intern use other- adj depreci adj less stock-bas comp oper inorgan revenu fx impact revenu jame rutherford analyst compani document stephen inc oper gross profit oper ebit oper ebitda oper net incom remov impact one-tim item restructur expens acquisit cost impact regular non-cash charg stock-bas compens amort purchas intang revenu model
inc segment model dollar million except per share data fyefyefyefyefyefyefor three month end fyefor three month end fyefor three month break-out revenu typesubscript servicescommerci cloud vault total subscript less gross stock-bas amort purchas intangibles- amort internal-us software- other- adj gross growth commerci cloud sub sub subscript revenu subscript revenu organ constant gross margin expans contract bpsadj gross gross margin expans contract bpsmetric subscript revenu retent rate growth exist custom growth custom ad growth growth exist custom net growth custom ad total profession servic othercommerci cloud vault total servic less gross stock-bas other- adj gross growth commerci cloud servic servic servic revenu servic revenu organ constant gross margin expans contract bpsadj gross gross margin expans contract profession servic total commerci veeva total less gross adj gross growth total revenu revenu organ constant cloud vault gross margin expans contract bpsadj gross gross margin expans contract bpsmetric commerci cloud vault fx impact revenu fx impact revenu qforma crowdlink zinc ahead add next acquisit here- inorgan revenu inorgan revenu rutherford analyst compani document stephen inc balanc sheet
inc balanc sheet dollar million except per share data fyefyefyefyefyefyefor three month end fyefor three month end fyefor three month equivalents- short-term investments- account receiv net- unbil account receivable- prepaid expens current assets- total current assets- properti equipment- defer cost net noncurrent- goodwill- intangibles- defer incom tax noncurrent- long-term assets- total assets- liabil stockhold equiti account payable- accru compens benefits- accru expens current liabilities- incom tax payable- defer revenue- total current liabilities- note payable- long-term liabilities- total liabilities- convert prefer stock- class common stock- class common stock- addit paid-in capital- accumul comprehens income- retain earnings- total stockhold equity- total liabilit stockhold equity- item day sale outstand dso day payabl outstand dpo defer revenue- growth growth summari total debt- net debt- net work capital- chang net work capital- total capitalization- total debt total debt ttm adj ebitda- jame rutherford analyst compani document stephen inc statement
inc statement dollar million except per share data fyefyefyefyefyefyefor three month end fyefor three month end fyefor three month activ net depreci stock base increas decreas current assets- increas decreas current liabilities- oper s- oper invest activ increas decreas investments- increas decreas certain long-term assets- increas decreas liabilities- capit capit fix asset adjustment- invest s- invest financ activ increas decreas long-term debt- dividends- stock buybacks- equiti adjustment- financ s- financ activities- effect fx- begin balance- chang end balance- free operations- less capit expenditures- free free growth dividends- dividend per basic dividend per share growth yoynmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmjam rutherford analyst compani document stephen inc capit
inc capit multipl dollar million except per share data capit current price capit target price fulli dilut share market total less excess ntmtotal adj free adj rutherford analyst closest possibl approxim calendar year endtrad multipl current pricetrad multipl target pricevaluationstephen inc estim compani mention
public public privat and/or intern list nametickerpricenametickerpricenameabbvi morgan agisticsaccentur plc class nippon telegraph telephon corpor sponsor align biopharmaadob nokia oyj sponsor apttusamazon com novarti ag sponsor bioclinicaappl open text cerimon pharmaceuticalsarqul emerg capitalatlassian corp plc class first groupautodesk highlin therapeuticsautomat data process informaticablackbaud ringcentr inc class magnet systemsceridian hcm hold salesforc com new ventur partnerscelgen sanofi sponsor parexelcornerston on-demand sap se sponsor pec venturesdxc technolog selecta bioscienc ppdebay shire plc sponsor sparta technologiesfireey shopifi inc class tpg biotechglaxosmithklin plc sponsor ultracel corpguidewir softwar vigil bioscienceshealthstream teva pharmaceut industri limit sponsor walsh wirelesshubspot thermo fisher scientif trade desk inc class ultim softwar group wix com medidata solut workday inc class in-depth report
analyst primarili respons prepar content report certifi view express report
accur reflect analyst person view subject compani secur ii part analyst compens
directli indirectli relat specif recommend view express analyst report
